These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 33934494)

  • 1. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
    Unseld M; Belic J; Pierer K; Zhou Q; Moser T; Bauer R; Piringer G; Gerger A; Siebenhüner A; Speicher M; Heitzer E; Prager GW
    Int J Cancer; 2021 Mar; 148(6):1452-1461. PubMed ID: 32949150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
    Khan K; Rata M; Cunningham D; Koh DM; Tunariu N; Hahne JC; Vlachogiannis G; Hedayat S; Marchetti S; Lampis A; Damavandi MD; Lote H; Rana I; Williams A; Eccles SA; Fontana E; Collins D; Eltahir Z; Rao S; Watkins D; Starling N; Thomas J; Kalaitzaki E; Fotiadis N; Begum R; Bali M; Rugge M; Temple E; Fassan M; Chau I; Braconi C; Valeri N
    Gut; 2018 Aug; 67(8):1484-1492. PubMed ID: 28790159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients.
    Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T
    BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Circulating DNA to Assess Prognoses for Metastatic Colorectal Cancer Patients Treated with Regorafenib Dose-Escalation Therapy: A Retrospective, Exploratory Analysis of the RECC Trial.
    Ohta R; Yamada T; Nakamura M; Enomoto M; Takahashi M; Yokomizo H; Kosugi C; Ishimaru K; Sonoda H; Kuramochi H; Yoshida Y; Furuya S; Hirata K; Yoshida H; Nozawa K; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
    Digestion; 2023; 104(3):233-242. PubMed ID: 36646047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.
    Lee DW; Lim Y; Kim HP; Kim SY; Roh H; Kang JK; Lee KH; Kim MJ; Ryoo SB; Park JW; Jeong SY; Park KJ; Kang GH; Han SW; Kim TY
    Cancer Res Treat; 2023 Jul; 55(3):927-938. PubMed ID: 36915247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer.
    Hedayat S; Cascione L; Cunningham D; Schirripa M; Lampis A; Hahne JC; Tunariu N; Hong SP; Marchetti S; Khan K; Fontana E; Angerilli V; Delrieux M; Nava Rodrigues D; Procaccio L; Rao S; Watkins D; Starling N; Chau I; Braconi C; Fotiadis N; Begum R; Guppy N; Howell L; Valenti M; Cribbes S; Kolozsvari B; Kirkin V; Lonardi S; Ghidini M; Passalacqua R; Elghadi R; Magnani L; Pinato DJ; Di Maggio F; Ghelardi F; Sottotetti E; Vetere G; Ciracì P; Vlachogiannis G; Pietrantonio F; Cremolini C; Cortellini A; Loupakis F; Fassan M; Valeri N
    Clin Cancer Res; 2024 May; 30(10):2140-2159. PubMed ID: 38376926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib.
    Wong AL; Lim JS; Sinha A; Gopinathan A; Lim R; Tan CS; Soh T; Venkatesh S; Titin C; Sapari NS; Lee SC; Yong WP; Tan DS; Pang B; Wang TT; Zee YK; Soong R; Trnkova Z; Lathia C; Thiery JP; Wilhelm S; Jeffers M; Goh BC
    J Transl Med; 2015 Feb; 13():57. PubMed ID: 25889309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and molecular assessment of regorafenib monotherapy.
    Kakizawa N; Suzuki K; Fukui T; Takayama Y; Ichida K; Muto Y; Hasegawa F; Watanabe F; Kikugawa R; Tsujinaka S; Futsuhara K; Miyakura Y; Noda H; Rikiyama T
    Oncol Rep; 2017 Apr; 37(4):2506-2512. PubMed ID: 28259999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib.
    Lim Y; Bang JI; Han SW; Paeng JC; Lee KH; Kim JH; Kang GH; Jeong SY; Park KJ; Kim TY
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):757-764. PubMed ID: 27888325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
    Raimondi L; Raimondi FM; Di Benedetto L; Cimino G; Spinelli GP
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib.
    Liu Y; Lyu J; Bell Burdett K; Sibley AB; Hatch AJ; Starr MD; Brady JC; Hammond K; Marmorino F; Rossini D; Goldberg RM; Falcone A; Cremolini C; Owzar K; Ivanova A; Moore DT; Lee MS; Sanoff HK; Innocenti F; Nixon AB
    Mol Cancer Ther; 2020 Oct; 19(10):2146-2154. PubMed ID: 32747417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial.
    Lueong SS; Herbst A; Liffers ST; Bielefeld N; Horn PA; Tannapfel A; Reinacher-Schick A; Hinke A; Hegewisch-Becker S; Kolligs FT; Siveke JT
    Clin Chem; 2020 Dec; 66(12):1510-1520. PubMed ID: 33257977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Cell Free DNA Integrity Index as a Biomarker for Response to Chemotherapy in Patients with Metastatic Colorectal Carcinoma.
    Eskander NS; Mansour L; Abdelaal A; Saad E; Mohamed D
    Asian Pac J Cancer Prev; 2022 Jan; 23(1):339-348. PubMed ID: 35092403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3'-Deoxy-3'-
    Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.